Chai Discovery

Tell me more about that.

Well, in these transcripts, Joshua Meyer and Matt McPartland, they're the founders of Chai Discovery, They make this very compelling case that we are completely moving away from drug discovery and entering the era of drug design.

Design, not discovery.

Exactly.

Myles is an investor and partner at Thrive Capital.

He has spent most of his career there investing in mostly software companies, including Cursor, Chai Discovery, Turbo Puffer, Benchling, GitHub, and many more.

Myles began his career at Thrive over a decade ago, but he also spent three years at another investment firm, Benchmark, before returning to Thrive in 2024.

I only met Miles recently, but over the years I've heard about him as one of the most impressive, thoughtful, driven, competitive venture investors out there.

And finally, Eli Lilly partnered with Amplitude Therapeutics to develop RNA vaccines for infectious diseases, with Lilly holding exclusive target-specific commercialization rights while Amplitude leads optimization and preclinical work.

Separately, Bristol Myers Squibb entered a collaboration with Chai Discovery to deploy AI molecular folding and design models across BMS's antibody discovery portfolio to accelerate the timeline from target identification to viable candidates.

And that's all for today's ACT Brief.

Join us tomorrow for more updates shaping clin ops and drug development.

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today's Pharmaceutical Executive Daily, a pharma collaboration roundup covers Amplitude Therapeutics' RNA vaccine partnership with Eli Lilly and Chai Discovery's AI antibody design collaboration with Bristol Myers Squibb.

Dan Chancellor of Norstella argues that deal-making has become a survival skill as pipeline productivity lags a five hundred billion dollar patent cliff and Pharmaceutical Executive breaks down what this week's rare disease and specialty drug news reveals about where the industry is heading.

Two AI and RNA-focused collaborations signal continued investment in platform partnerships this week.

Amplitude Therapeutics has entered a strategic research collaboration with Eli Lilly and Company to develop trans-amplifying RNA, or taRNA, vaccines for infectious diseases.

With Lilly taking exclusive commercialization rights and the option to add up to two additional targets.

Separately, Chai Discovery has agreed to let Bristol Myers Squibb deploy its AI models for molecular folding and design across its antibody discovery portfolio, an effort BMS says will speed the path from concept to viable therapeutic candidates.

Dan Chancellor, vice president of thought leadership at Norstella, argues that deal-making has become a survival skill for pharma as pipeline productivity fails to keep pace with a looming five hundred billion dollar patent cliff between twenty twenty-six and twenty thirty-two.